GSK3B and neoplasm: Aberrant overexpression of GSK-3β promotes tumour growth and chemotherapy resistance in a spectrum of solid tumours through differential effects on pro-survival NF-κB and c-Myc pathways as well as on TNF-related apoptosis-inducing ligand (TRAIL) and p53-mediated apoptotic mechanisms [4, 6].